Allogene Therapeutics (ALLO) Research & Development (2018 - 2026)

Allogene Therapeutics has reported Research & Development for 9 years, with the latest figure at $32.0 million in Q1 2026.

• Quarterly Research & Development fell 36.25% year-over-year to $32.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $132.0 million (down 30.64% YoY) and the FY2025 annual result came in at $150.2 million, down 21.92% from the prior year.
• Research & Development advanced to $32.0 million in Q1 2026 per ALLO's latest filing, from $28.6 million in the prior quarter.
• Over five years, Research & Development peaked at $80.2 million in Q1 2023 and troughed at $28.6 million in Q4 2025.
• A 5-year average of $51.4 million and a median of $50.4 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 39.71% in 2022, then slumped 36.33% in 2025.
• Over 5 years, Research & Development stood at $75.4 million in 2022, then dropped by 27.52% to $54.7 million in 2023, then declined by 17.73% to $45.0 million in 2024, then plunged by 36.33% to $28.6 million in 2025, then climbed by 11.77% to $32.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $32.0 million, $28.6 million, and $31.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.